I found this 'threat assessment brief' re the Indian VOCs (focusing on the EU):
www.ecdc.europa.eu/sites/default/files/documents/Emergence-of-SARS-CoV-2-B.1.617-variants-in-India-and-situation-in-the-EUEEA.pdf
Quote:
Summary:
First reported in India in December 2020, SARS-CoV-2 lineages B.1.617.1, B.1.617.2 and B.1.617.3 have been increasingly detected in other countries.
• The aim of this Threat Assessment Brief is to assess the potential public health implications of the B.1.617
lineages for EU/EEA countries with a focus on lineage B.1.617.2.
• Over the past eight weeks India and some surrounding countries have seen a sharp increase in the number of reported SARS-CoV-2 cases and deaths. This has been associated with a rising proportion of sequenced
viruses belonging to lineages B.1.617.1 and B.1.617.2.
• The United Kingdom has seen a rapid increase in detection of lineage B.1.617.1 and, to a greater extent, B.1.617.2, associated with travel to India and onward community transmission. On the 6 May, the United
Kingdom (UK) designated lineage B.1.617.2 as a variant of concern.
• In the EU/EEA there are indications that the frequency of detection of both lineages B.1.617.1 and B.1.617.2 is increasing.
• Currently described lineages B.1.617.1, B.1.617.2 and B.1.617.3 have distinct mutation profiles and warrant individual assessment. Given the still very limited available data with respect to their transmissibility, disease severity and immune escape potential relative to other co-circulating SARS-CoV-2 variants in the EU/EEA, the full impact of these lineages on public health is not yet possible to assess.
• At this time, ECDC maintains its assessment of B.1.617.1, B.1.617.2 and B.1.617.3 as variants of interest and will continue to actively monitor the situation.
Specific to the UK:
Quote:
Public Heath England (PHE) consider that B.1.617.2 is at least as transmissible as B.1.1.7 (currently the dominant variant in the UK). This assessment was based on evidence that the variant B.1.617.2 can compete with B.1.1.7 in the population, as well as on modelled growth estimates [17]. The assessment was made with ‘moderate confidence’ and it highlighted the need for further analyses to confirm this observation.
Growth estimates, based on a logistic growth model for variants of concern relative to a B.1.1.7 baseline for B.1.617.1, were estimated by
PHE on 20 April 2021 to be 0.51 (n=21; p=0.006) [17]. No growth rate assessment or any other transmissibility estimate is available from PHE for B.1.617.3.
Furthermore, all three lineages contain the mutations L452R and D614G, which are both associated with increased transmissibility.
Factors that may have increased the detections of all three lineages in the UK in recent weeks include increased travel to/from India for religious and other large gatherings [18].
Targeted testing of arrivals from India to the UK and countries in the EU/EEA may have caused an overrepresentation of all three lineages among cases detected and sequenced and further data are needed to assess their true incidence and transmissibility.
There is currently no in vitro neutralisation data evaluating the immune escape potential of B.1.617.2 against serum from previously infected or vaccinated individuals. Available evidence exists only for B.1.617.1, where serum from previously infected and vaccinated individuals has been shown to neutralise B.1.617.1 equally, or more effectively than other currently circulating variants of concern.